Skip to navigation Skip to content
  • The Cancer Letter on Facebook
  • The Cancer Letter on Twitter
  • The Cancer Letter on LinkedIn

The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
  • SUBSCRIBE
  • Login
  • SUBSCRIBE
  • Login
The Cancer Letter
Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
Funding Opportunities

FDA opens application for Orphan Products Clinical Trials Grant Program

September 15, 2023
Vol.49 No.34
Drugs & Targets

FDA grants accelerated approval to Elrexfio for r/r multiple myeloma

September 08, 2023
Vol.49 No.33
Drugs & Targets

FDA places partial clinical hold for magrolimab studies in AML

September 08, 2023
Vol.49 No.33
Drugs & Targets

FDA expands Reblozyl’s indication to first-line treatment of anemia in lower-risk myelodysplastic syndromes

September 08, 2023
Vol.49 No.33
Drugs & Targets

FDA clears AION’s continuous temperature monitoring device and software platform

September 08, 2023
Vol.49 No.33
Drugs & Targets

FDA grants priority review to Tibsovo for MDS

September 08, 2023
Vol.49 No.33
Drugs & TargetsFree

FDA grants accelerated approval to Talvey for R/R multiple myeloma

August 11, 2023
Vol.49 No.32
Drugs & TargetsFree

FDA approves Gavreto for NSCLC with RET gene fusions

August 11, 2023
Vol.49 No.32
Drugs & TargetsFree

FDA approves companion diagnostic to Ayvakit in gastrointestinal stromal tumors

August 11, 2023
Vol.49 No.32
Drugs & TargetsFree

FDA accepts Astellas’s sNDA for Cresemba in children

August 11, 2023
Vol.49 No.32

Posts navigation

Previous1…464748…64Next

Trending Stories

  • From “default dead” to living the future of cancer care
    As founding CEO of GitLab, I went “founder mode” on my osteosarcoma
  • Trump’s tariffs on generic drugs are “another wrinkle in an already unstable system”
  • A new AI tool enables speedy use of ASCO guidelines, eliminating typical errors
  • NCAB asks for help from administration as NCI deals with deluge of grant applications
  • Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
  • Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case

ABOUT
ABOUT
About The Cancer Letter
Accessibility Statement
Our Contributors
Editorial policies
Store
SUBSCRIPTIONS
SUBSCRIPTIONS
Our readers
Pricing
News alerts
About IP login
Job board
CONTACT
CONTACT
Contact us
Submission guidelines
Advertise
Careers
SEE ALSO
Cancer History Project
The Cancer Letter
Copyright © 2026 The Cancer Letter Inc. All rights reserved.
Privacy Policy
Terms & Conditions
FOLLOW US
Instagram
Twitter
LinkedIn
Facebook
Vimeo
Scroll to top
Request Cancellation

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Renew today!

Your subscription has lapsed. Subscribe today to access this content.
SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.
LOGINSUBSCRIBE NOW
SEARCH DATE
SEARCH TEXT
      Cancel
      OK
      Cancel
      OK
      Delete Account
      Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below
      No

      Never miss an issue!

      Get alerts for our award-winning coverage in your inbox.

      Login

       
      Forgot Password?

      Site license subscribers:
      Log in with your IP | Register a sponsored account